Attendee search 

Angelini, established in 1919, is a privately-held, family owned international Group with a consolidated revenue for 2017 of € 1,7 billion. Pharma represents the core business of Angelini family, with a revenue of € 851 million.

Headquartered in Rome, Italy, Angelini Pharma is a fully integrated company from R&D to Commercial and operates directly in more than twenty countries, including Italy, Spain, Central Eastern European countries, Russia and Turkey.

Angelini focuses his research and commercial activities mainly on Pain, Infectious Diseases and Central Nervous System.

R&D Department has full development capabilities from discovery to clinical and it has currently development programs ongoing in all the core therapeutic areas. Amongst others, R&D synthetized and developed both Benzydamine- for treatment of Sore throat- and Trazodone- for treatment of Major Depression- two molecules worldwide present either through Angelini direct operations or licensing-out deals.

Angelini field force- that counts more than 1.100 professionals - promotes a wide range of products coming both from internal development and licensing agreements, targeting and detailing a number of Healthcare professionals ranging from Pharmacist and General Practitioner to specialty care physicians of Psychiatry, Neurology, Infectious Disease, Pain, Oncology, Paediatric and Gynaecology.

Angelini represents a partner of choice for new product licenses for its territories with ready-to-use capabilities in terms of Regulatory, Market Access, Medical and Commercial. A list of partners of Angelini includes amongst others Helsinn, Incyte, Allergan, Dainippon Sunovion, Gilead, Zambon, Fidia, Almirall and Expanscience. Business Development is looking for innovative products in late stage development in Pain, Infectious Disease and CNS with companies interested in long-term partnership. M&A and Divestment opportunities are also in the scope when there’s a fitting to Angelini focus and Geography.

Liberty Pharma group is a French family business specialised in the development and manufacturing of finished products, with various status, from pharmaceutical to food supplement.

We are offering a full service (MA Dossier + Supply) to partners willing to create and complement their range with products that we offer.

Among others, we are working with multinational companies such as Servier, Mylan, Teva, BMS, Sanofi, Sandoz which appreciate our full service reactivity and quality.

Liberty Pharma offers several kind of products. Our Product list, available on demand, features :
- Medical mouthwashes
- Cough and cold products : pharmaceutical, phytotherapy, medical device and also food supplement
- Gastro-enterology products : both pharmaceutical and phytotherapy
- Venous pathologies : Food supplement range
- Dermatology : Scabies treatment

Each dossier is fully developed internally and is available to be audited in our online platform. We are looking for partners interested by the MA Dossiers / finished products that we offer, with a supply full service in order to launch innovative and unique products or to complete an existing range.

Our standard business model is open to discussion but normally we sell directly MA Dossiers, to our partners, combined with a long-term supply contract.
We don't have any trademarks or sales force, nor interest in licensing-in.

NATRAPHARM,  Philippines www.natrapharm.com

Core objective: To market pharmaceutical products through licensing and/or supply agreement with reputable international companies.

Organization: The total headcount is 600, among which 518 are field personnel and 82 in head office (top executives, marketing, registration, finance and HR).

NATRAPHARM Inc. is mainly focussing on antiinfectives, antibiotics, anti-asthma, anti-allergy, pediatricians. The management, the distribution and the services are common to both companies, Natrapharm Inc. and Patriot Pharmaceutical corporation. PATRIOT PHARMACEUTICAL CORPORATION handles cardiology and metabolic, neurology, psychiatry, surgery, pain management, and nephrology.

Sales performance: Natrapharm Group has one of the highest growth rate of the ethical market.

Natrapharm Group is ranking between the 10 leading pharmaceutical companies with more than 70 million US$ (combined drugstore and hospital sales less OTC) and is 2nd largest Filipino pharmaceutical company in the Ethical Segment.

Natrapharm expertise & strengths:

Long experience of partnership with multinational companies

An efficient registration department.

Own distribution.

A strong, well trained and motivated promotional force

Licensors: International companies having licensed products to Natrapharm e.g.

Sanofi-Aventis (Phils.), Abbott (Phils.), Ferrer Laboratorios (Spain), Apotex (Canada), MSD (Phils.), Stada (Germany), Samjin (Korea), Ildong (Korea)

We offer:

The organisation has been built in such a way, that NATRAPHARM has the capacity to market quickly additional products and /lines from new principals.

Products:

They have to fit inside NATRAPHARM/PATRIOT current lines and not to compete internally.

They are not necessarily new products but must be marketed in their country of origin and have an up to date registration dossier.

They can also be products already marketed in the Philippines but which is either very little or no longer promoted by the principal due to other priorities.

NATRAPHARM can either take care of a new line if the products can reach a certain level of growth or NATRAPHARM can host the line. In such case, the responsibility remains with the principal.

In any case , NATRAPHARM is looking for a long term relationship between the principal and NATRAPHARM. NATRAPHARM as 2nd largest Pilipino ethical company is open for co-marketing of innovative products from multinationals.

We are interested in:

Ethical, unique, add-on generic products (also niche products) as well as medical food with indication and clinical trials, metoprolol, clonidine, diltiazem, rosuvastatin, nicardipine inj. with CDT format dossier, climate zone IV stability.

Contact:

Dr. Thomas Högn

International Advisor and Member of the Executive Committee

Natrapharm, Inc., Philippines

Moselstrasse 5

50859 Köln

Germany

Tel.: +49 (0) 172 2910525

e-mail: thomashoegn@gmx.com

Alliance Pharma is an internation specialty pharma busienss with a buy and build business model and asset light operations. We have a balanced portoflio of growth focussed international star brands and a cash-generative Bedrock requiring minimal promotional support. We have 20 years of operation, 35 deals experience and have been on the London stock exchange junior market (AIM) since 2003 (LSE: APH). 2017 results: £100m+ sales, 27% EBITDA, £20m+ FCF, dividend paying Our star brands are: Kelo-cote – fastest drying, silicone gel anti-scar treatment  MacuShield – exact match to the protective pigments found on the macula Vamousse – most technologically advanced treatment for head lice Nizoral – medicated anti-dandruff shampoo acquired from J&J in June 2018      

We will give you all the power you need to run your partnering, investment and funding activities backed up by our experienced valuation team, solid and proven valuation tool. Xplico Evaluator is an easy-to-use, flexible MS Excel-based valuation tool with integrated risk assessment and powerful analysis features for the life science industry.

 

Our Biotech package includes valuation tool, training and valuation support for a low fixed monthly fee. 

We will be able to support you with latest market and benchmark data, build and review business cases and step in if you are short of resources. 

We can evaluate your projects and/or company for a fixed competitive fee or support you during partnering negotiations.

 

Xplico was established in 2005 with the purpose of develop and market an easy-to-use and standardized tool for valuation of project and portfolio in the life science industry. Xplico is today the market leader in valuation supporting more than 75 life science companies in Europe and US on a day to day basis

Our team today has unique extensive experience in valuation, forecasting and project/portfolio management, as well as in-depth knowledge of business processes in the life science industry, information technology and financial systems.